NOVONESIS (NOVOZYMES) B (NVZMF) Financials
NVZMF Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 4.2 billion | 2.1 billion |
2023-09-30 | 4.0 billion | 1.9 billion |
2023-06-30 | 4.1 billion | 2.1 billion |
2023-03-31 | 4.1 billion | 2.2 billion |
NVZMF Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 76.7 million | ? |
2023-09-30 | 157.5 million | ? |
2023-06-30 | 84.9 million | ? |
2023-03-31 | -16.7 million | ? |
NVZMF Net Income
Date | Net Income |
---|---|
2023-12-31 | 102.9 million |
2023-09-30 | 131.7 million |
2023-06-30 | 89.7 million |
2023-03-31 | 117.3 million |
NVZMF Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 171.1 million | - | 54.6 million |
2023-09-30 | 168.9 million | - | 53.0 million |
2023-06-30 | 162.3 million | - | 57.6 million |
2023-03-31 | 173.3 million | - | 60.3 million |
NVZMF Shares Outstanding
NVZMF Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 89.4 million | 77.6 million | 35.7 million | 89.0 million |
2023-09-30 | 67.4 million | 65.4 million | 33.5 million | 75.3 million |
2023-06-30 | 80.2 million | 75.2 million | 33.7 million | 86.8 million |
2023-03-31 | 62.7 million | 75.7 million | 36.7 million | 93.6 million |
NVZMF Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 681.5 million | 313.6 million |
2023-09-30 | 631.8 million | 291.8 million |
2023-06-30 | 616.1 million | 274.8 million |
2023-03-31 | 676.8 million | 310.4 million |
NVZMF
Price: $62.09
Forward Dividend Yield: 0.47%
Payout Ratio: 18.08%
Dividend Per Share: 0.29 USD
Earnings Per Share: 1.57 USD
P/E Ratio: 31.45
Exchange: PNK
Sector: Basic Materials
Industry: Specialty Chemicals
Market Capitalization: 28.0 billion
Average Dividend Frequency: 1
Years Paying Dividends: 16
DGR3: 3.23%
DGR5: 2.59%
DGR10: -30.00%